Moderna, Inc. (MRNA) 今日盘前股价大幅上涨5.28%，引起了市场的广泛关注。
消息面上，美国食品和药物管理局（FDA）已同意对Moderna公司的季节性流感疫苗mRNA-1010进行审查。此前，FDA曾以试验设计存在缺陷为由拒绝了审查申请，而此次公司提交了修改后的方案，寻求全面批准该疫苗用于50至64岁人群，并加速批准用于65岁及以上人群，同时承诺在上市后进行额外的研究。
这一监管进展被视为公司产品管线推进的重要一步。如果获得批准，该疫苗最早可能在2026/27年流感季节上市，为Moderna带来新的增长动力。欧洲、加拿大和澳大利亚的监管机构也在同步审查该候选疫苗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.